REPORTS: Martin Shkreli, the former pharma executive everyone loves to hate, may face new charges
AP Photo/Richard Drew
Shkreli already faces charges he defrauded investors, but his lawyers said Tuesday that a trial should be delayed, as there may be new charges filed.
CNBC reports those additional charges against Shkreli and lawyer Evan Greebel should be announced within the month.
To recap, Shkreli has been charged by the federal government with seven counts:
- 2 counts of securities fraud
- 2 counts of conspiracy to commit securities fraud
- 3 counts of conspiracy to commit wire fraud.
Shkreli, the notorious former pharma CEO, made headlines last September after he raised the price of Daraprim, a drug used to treat a parasitic infection called toxoplasmosis, by 5,000%. These charges, however, are not directly related to the price hike, but to events that happened earlier in his career, while he was managing hedge funds.
Shkreli's next court appearance is scheduled for June 6, CNBC reports.
- A centenarian who starts her day with gentle exercise and loves walks shares 5 longevity tips, including staying single
- A couple accidentally shipped their cat in an Amazon return package. It arrived safely 6 days later, hundreds of miles away.
- FSSAI in process of collecting pan-India samples of Nestle's Cerelac baby cereals: CEO
- India's e-commerce market set to skyrocket as the country's digital economy surges to USD 1 Trillion by 2030
- Top 5 places to visit near Rishikesh
- Indian economy remains in bright spot: Ministry of Finance
- A surprise visit: Tesla CEO Elon Musk heads to China after deferring India visit
- Unemployment among Indian youth is high, but it is transient: RBI MPC member